CCI, Mankind Pharma
Mankind Pharma-BSV acquisition: Major merger update from CCI – Details
In an official statement, the CCI said the proposed transaction involves the acquisition of 100% per cent shareholding of Bharat Serums and Vaccines Limited (BSV) by Mankind Pharma Ltd (Proposed Combination).
Mankind Pharma shares extend gain on CCI nod for BSV acquisition
The CCI has cleared Mankind Pharma's proposed acquisition of 100% stake in Bharat Serums and Vaccines for ₹13,630 crore.
Mankind Pharma gets CCI nod for BSV acquisition
Mankind Pharma Ltd. receives regulatory approvals for 100% acquisition of Bharat Serums and Vaccines Ltd. worth ₹13,630 crore.
CCI Approves Mankind Pharma's Acquisition Of Bharat Serums And Vaccines For Rs 13,630 Crore
BSV is also recognized as a leader in women's healthcare, assisted reproductive treatments, and critical care.
Mankind Pharma board approves fundraising plan of up to Rs 10,000 cr
Mankind Pharma on Monday said it will raise up to Rs 10,000 crore via issuance of non-convertible debentures and commercial papers.
Mankind Pharma-BSV Acquisition: Rs 10,000 crore update from India’s 4th largest drug maker
In a regulatory filing to stock exchanges today, Mankind Pharma Ltd, the fourth-largest pharmaceutical company in India by market share, said that its board has approved raising up to Rs 5,000 crore through non-convertible debentures in 3-4 distinct series with maturities of upto 48 months.
Mankind Pharma's ₹13,630 crore acquisition of Bharat Serums and Vaccines approved by CCI
The Competition Commission of India has approved Mankind Pharma's ₹13,630 crore acquisition of Bharat Serums and Vaccines.
CCI clears Rs 13,630-crore Mankind Pharma-Bharat Serums Vaccines deal
In July this year, Mankind Pharma announced that it will fully acquire Bharat Serums and Vaccines from private equity firm Advent International for around Rs 13,630 crore.
Mankind Pharma shares in focus as company approves Rs 10,000 crore fundraise plan
The company's board of directors on Monday approved raising up to Rs 5,000 crore via non-convertible debentures in 3-4 distinct series with maturities of up to 48 months, in a regulatory filing to stock exchanges.
AFAQS1d
Mankind Pharma moves OTC business to subsidiary Mankind Consumer Products
This realignment is part of a broader strategy to enhance focus on the consumer business, which currently contributes 7% to ...
Stocks to Watch: Mankind Pharma, Suzlon Energy, Adani Enterprises, Godrej Properties, and more
Here’s a quick look at stocks likely to be in focus in today's trade. Mankind Pharma has received the necessary regulatory ...
Mankind Pharma transfers OTC biz to subsidiary Mankind Consumer Products
Mankind Pharma transfers OTC business to subsidiary, focuses on consumer products, raises funds through debentures and ...
The Financial Express3d
Mankind Pharma transfers OTC Business to subsidiary Mankind Consumer Products Private Limited
Mankind Pharma’s consumer products portfolio includes several trusted brands Manforce, HealthOK, Prega News, AcneStar, ...
Fortune India4d
Mankind Pharma board approves raising of ₹10,000 cr via private placement
Mankind Pharma's Q1 profit surged 10% YoY to ₹543 crore; brokerage Motilal Oswal expects 14% earnings CAGR over FY24-26 ...
devdiscourse4d
Mankind Pharma to Raise ₹5,000 Crore Via Non-Convertible Debentures and Commercial Papers
Mankind Pharma will issue non-convertible debentures (NCDs) and commercial papers (CP) worth ₹5,000 crore. These funds will ...
Mankind may end up spinning out a winner in consumer brands unit
The company entered the OTC business in 2007 and it has grown to have established brands such as Manforce, HealthOK, Prega ...